Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 24, pp. 2731 - 2740
There is little information concerning infective endocarditis (IE) in patients with bicuspid aortic valve (BAV) or mitral valve prolapse (MVP). Currently, IE...
antibiotic prophylaxis | endocarditis | mitral valve prolapse | bicuspid aortic valve | CARDIAC & CARDIOVASCULAR SYSTEMS | GUIDELINES | PREVENTION | RISK | MICROBIOLOGY | AMERICAN-HEART-ASSOCIATION | ANTIBIOTIC-PROPHYLAXIS | STREPTOCOCCI | BACTERIAL-ENDOCARDITIS | RECOMMENDATIONS | TEMPORAL TRENDS | Aortic Valve - abnormalities | Humans | Middle Aged | Mitral Valve Prolapse - complications | Male | Antibiotic Prophylaxis | Endocarditis - microbiology | Endocarditis - prevention & control | Heart Valve Diseases - complications | Adult | Female | Registries | Aged | Infective endocarditis | Care and treatment | Mitral valve prolapse | Analysis | Heart failure | Prostheses | Mitral valve | Statistical analysis | Risk groups | Heart surgery | Complications | Indication | Embolisms | Mortality | Prophylaxis | Risk | Patients | Heart valves | Microorganisms | Hospitals | Antibiotics | Endocarditis | Aorta | Aortic valve
antibiotic prophylaxis | endocarditis | mitral valve prolapse | bicuspid aortic valve | CARDIAC & CARDIOVASCULAR SYSTEMS | GUIDELINES | PREVENTION | RISK | MICROBIOLOGY | AMERICAN-HEART-ASSOCIATION | ANTIBIOTIC-PROPHYLAXIS | STREPTOCOCCI | BACTERIAL-ENDOCARDITIS | RECOMMENDATIONS | TEMPORAL TRENDS | Aortic Valve - abnormalities | Humans | Middle Aged | Mitral Valve Prolapse - complications | Male | Antibiotic Prophylaxis | Endocarditis - microbiology | Endocarditis - prevention & control | Heart Valve Diseases - complications | Adult | Female | Registries | Aged | Infective endocarditis | Care and treatment | Mitral valve prolapse | Analysis | Heart failure | Prostheses | Mitral valve | Statistical analysis | Risk groups | Heart surgery | Complications | Indication | Embolisms | Mortality | Prophylaxis | Risk | Patients | Heart valves | Microorganisms | Hospitals | Antibiotics | Endocarditis | Aorta | Aortic valve
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 06/2019, Volume 64, pp. 63 - 71
The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson...
Charlson index | Comorbidity | Surgery | Age | Endocarditis | CRITERIA | DIAGNOSIS | PROSTHETIC VALVE ENDOCARDITIS | MANAGEMENT | OLD | CO-MORBIDITY | MEDICINE, GENERAL & INTERNAL | INDEX | ELDERLY-PATIENTS | EPIDEMIOLOGY | Patient outcomes | Mortality
Charlson index | Comorbidity | Surgery | Age | Endocarditis | CRITERIA | DIAGNOSIS | PROSTHETIC VALVE ENDOCARDITIS | MANAGEMENT | OLD | CO-MORBIDITY | MEDICINE, GENERAL & INTERNAL | INDEX | ELDERLY-PATIENTS | EPIDEMIOLOGY | Patient outcomes | Mortality
Journal Article
Medicine (United States), ISSN 0025-7974, 2015, Volume 94, Issue 43, p. e1816
The aim of the study was to describe the epidemiologic and clinical characteristics and identify the risk factors of short-term and 1-year mortality in a...
MORTALITY | SURGERY | STATEMENT | DIAGNOSIS | EUROSCORE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | CARDIOLOGY | PROGNOSIS | HEALTH-CARE PROFESSIONALS | Heart Valve Diseases - microbiology | Prospective Studies | Humans | Middle Aged | Risk Factors | Male | Endocarditis - microbiology | Endocarditis - diagnosis | Heart Valve Prosthesis - microbiology | Spain - epidemiology | Endocarditis - mortality | Heart Valve Diseases - mortality | Female | Aged | Heart Valve Diseases - diagnosis | Heart | Care and treatment | Usage | Surgery | Infective endocarditis | Research | Health aspects | Risk factors
MORTALITY | SURGERY | STATEMENT | DIAGNOSIS | EUROSCORE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | CARDIOLOGY | PROGNOSIS | HEALTH-CARE PROFESSIONALS | Heart Valve Diseases - microbiology | Prospective Studies | Humans | Middle Aged | Risk Factors | Male | Endocarditis - microbiology | Endocarditis - diagnosis | Heart Valve Prosthesis - microbiology | Spain - epidemiology | Endocarditis - mortality | Heart Valve Diseases - mortality | Female | Aged | Heart Valve Diseases - diagnosis | Heart | Care and treatment | Usage | Surgery | Infective endocarditis | Research | Health aspects | Risk factors
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 11/2014, Volume 32, Issue 9, pp. 579 - 582
Introduction: Drugs like statins may induce rhabdomyolysis. Simvastatin and lovastatin have a high hepatic metabolism and their potential toxicity could be...
Antiretroviral drugs | Ritonavir | Simvastatin | Renal failure | Drug-drug interactions | Human immunodeficiency virus | Hydroxymethylglutaryl-CoA reductase inhibitors | Rhabdomyolysis | Hepatotoxicity | Statins
Antiretroviral drugs | Ritonavir | Simvastatin | Renal failure | Drug-drug interactions | Human immunodeficiency virus | Hydroxymethylglutaryl-CoA reductase inhibitors | Rhabdomyolysis | Hepatotoxicity | Statins
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 03/2018, Volume 66, Issue 6, pp. 825 - 832
Prosthetic valve Candida spp. endocarditis is rare but remains severe, with a 6-month mortality rate of 34%. Liposomal amphotericin B-based "induction"...
Candida | endocarditis | prosthetic valve | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | MICROBIOLOGY | FUNGAL ENDOCARDITIS | IMMUNOLOGY | GUIDELINE | THERAPY | INFECTIVE ENDOCARDITIS | FLUCONAZOLE
Candida | endocarditis | prosthetic valve | DIAGNOSIS | INFECTIOUS DISEASES | MANAGEMENT | MICROBIOLOGY | FUNGAL ENDOCARDITIS | IMMUNOLOGY | GUIDELINE | THERAPY | INFECTIVE ENDOCARDITIS | FLUCONAZOLE
Journal Article
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 06/2019, Volume 74, Issue 6, pp. 1713 - 1717
Objectives: Tropheryma whipplei has been detected in 3.5% of the blood culture-negative cases of endocarditis in Spain. Experience in the management of T....
DIAGNOSIS | INFECTIOUS DISEASES | TRIMETHOPRIM | RESISTANCE | TRIMETHOPRIM/SULFAMETHOXAZOLE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS
DIAGNOSIS | INFECTIOUS DISEASES | TRIMETHOPRIM | RESISTANCE | TRIMETHOPRIM/SULFAMETHOXAZOLE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTIVE ENDOCARDITIS
Journal Article
Medicina clinica, 10/2017, Volume 149, Issue 8, p. 331
The possible renal toxicity of certain antibiotics (AB) is well known. The objective of our work is to know the possible effect of AB treatments in the...
Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Humans | Middle Aged | Risk Factors | Endocarditis, Bacterial - diagnosis | Male | Treatment Outcome | Gram-Positive Bacterial Infections - diagnosis | Anti-Bacterial Agents - therapeutic use | Staphylococcal Infections - diagnosis | Renal Insufficiency - chemically induced | Streptococcal Infections - diagnosis | Enterococcus - isolation & purification | Aged, 80 and over | Female | Registries | Streptococcal Infections - drug therapy | Aged | Anti-Bacterial Agents - adverse effects | Gram-Positive Bacterial Infections - drug therapy
Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Humans | Middle Aged | Risk Factors | Endocarditis, Bacterial - diagnosis | Male | Treatment Outcome | Gram-Positive Bacterial Infections - diagnosis | Anti-Bacterial Agents - therapeutic use | Staphylococcal Infections - diagnosis | Renal Insufficiency - chemically induced | Streptococcal Infections - diagnosis | Enterococcus - isolation & purification | Aged, 80 and over | Female | Registries | Streptococcal Infections - drug therapy | Aged | Anti-Bacterial Agents - adverse effects | Gram-Positive Bacterial Infections - drug therapy
Journal Article
Social Science & Medicine, ISSN 0277-9536, 10/2019, Volume 238, p. 112367
García Márquez's novel, “Chronicle of a Death Foretold”, narrates the multiple strands of a story leading up to a murder in a small Caribbean village. The...
Social determinants of health | Disaster | Environment and public health | Puerto Rico | Hurricanes | Colonialism | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SOCIAL SCIENCES, BIOMEDICAL | MARIA | CARE | Death & dying | Social control | Poverty | Health problems | Pensions | Health education | Housing | Unemployment | Neoliberalism | Exploitation | Quality of life | Social inequality | Discrimination | Disasters | Homicide | Privatization | Equality | Racism | Public health
Social determinants of health | Disaster | Environment and public health | Puerto Rico | Hurricanes | Colonialism | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | SOCIAL SCIENCES, BIOMEDICAL | MARIA | CARE | Death & dying | Social control | Poverty | Health problems | Pensions | Health education | Housing | Unemployment | Neoliberalism | Exploitation | Quality of life | Social inequality | Discrimination | Disasters | Homicide | Privatization | Equality | Racism | Public health
Journal Article
MEDICINE, ISSN 0025-7974, 06/2016, Volume 95, Issue 26, p. e4008
Infective endocarditis (IE) complicating hypertrophic cardiomyopathy (HCM) is a poorly known entity. Although current guidelines do not recommend IE antibiotic...
BACTERIAL-ENDOCARDITIS | PROPHYLAXIS | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | GUIDELINES | PREVENTION | antibiotic prophylaxis | endocarditis | hypertrophic cardiomyopathy | Endocarditis, Bacterial - etiology | Prospective Studies | Humans | Middle Aged | Female | Male | Aged | Cardiomyopathy, Hypertrophic - complications | Cohort Studies | Complications and side effects | Cohort analysis | Usage | Cardiomyopathy, Hypertrophic | Antibiotics | Infective endocarditis | Dosage and administration | Risk factors
BACTERIAL-ENDOCARDITIS | PROPHYLAXIS | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | RECOMMENDATIONS | GUIDELINES | PREVENTION | antibiotic prophylaxis | endocarditis | hypertrophic cardiomyopathy | Endocarditis, Bacterial - etiology | Prospective Studies | Humans | Middle Aged | Female | Male | Aged | Cardiomyopathy, Hypertrophic - complications | Cohort Studies | Complications and side effects | Cohort analysis | Usage | Cardiomyopathy, Hypertrophic | Antibiotics | Infective endocarditis | Dosage and administration | Risk factors
Journal Article
Enfermedades Infecciosas y Microbiologia Clinica, ISSN 0213-005X, 05/2012, Volume 30, Issue 5, pp. 265 - 267
Journal Article
Medicine (United States), ISSN 0025-7974, 06/2016, Volume 95, Issue 26
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2014, Volume 58, Issue 12, pp. 1668 - 1675
Background. Staphylococcus aureus endocarditis has a high mortality rate. Vancomycin minimum inhibitory concentration (MIC) has been shown to affect the...
mortality | methicillin-susceptible Staphylococcus aureus | left-sided endocarditis | vancomycin minimal inhibitory concentration | cloxacillin | DIAGNOSIS | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | RESISTANT | THERAPY | BACTEREMIA | BACTERIAL GENOTYPE | COMPLICATIONS | INFECTIVE ENDOCARDITIS | ASSOCIATION | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Hospital Mortality | Humans | Middle Aged | Male | Survival Rate | Cloxacillin - pharmacology | Microbial Sensitivity Tests | Daptomycin - pharmacology | Vancomycin - pharmacology | Endocarditis, Bacterial - microbiology | Adult | Female | Aged | Anti-Bacterial Agents - pharmacology | Retrospective Studies | Staphylococcal Infections - microbiology | Staphylococcus aureus - drug effects | Usage | Care and treatment | Mortality | Analysis | Endocarditis | Vancomycin | Research | Health aspects | Staphylococcus aureus
mortality | methicillin-susceptible Staphylococcus aureus | left-sided endocarditis | vancomycin minimal inhibitory concentration | cloxacillin | DIAGNOSIS | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | RESISTANT | THERAPY | BACTEREMIA | BACTERIAL GENOTYPE | COMPLICATIONS | INFECTIVE ENDOCARDITIS | ASSOCIATION | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Hospital Mortality | Humans | Middle Aged | Male | Survival Rate | Cloxacillin - pharmacology | Microbial Sensitivity Tests | Daptomycin - pharmacology | Vancomycin - pharmacology | Endocarditis, Bacterial - microbiology | Adult | Female | Aged | Anti-Bacterial Agents - pharmacology | Retrospective Studies | Staphylococcal Infections - microbiology | Staphylococcus aureus - drug effects | Usage | Care and treatment | Mortality | Analysis | Endocarditis | Vancomycin | Research | Health aspects | Staphylococcus aureus
Journal Article
Enfermedades infecciosas y microbiologia clinica, 11/2014, Volume 32, Issue 9, p. 579
Drugs like statins may induce rhabdomyolysis. Simvastatin and lovastatin have a high hepatic metabolism and their potential toxicity could be increased by...
Kidney Tubular Necrosis, Acute - chemically induced | Simvastatin - therapeutic use | Simvastatin - adverse effects | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Humans | Middle Aged | Atorvastatin Calcium - economics | Simvastatin - economics | Simvastatin - pharmacology | Contraindications | HIV Protease Inhibitors - pharmacology | Ritonavir - adverse effects | Ritonavir - therapeutic use | Female | Ritonavir - pharmacology | Drug Substitution - adverse effects | Atorvastatin Calcium - therapeutic use | Chemical and Drug Induced Liver Injury - etiology | HIV Protease Inhibitors - adverse effects | Chemical and Drug Induced Liver Injury - prevention & control | Dyslipidemias - drug therapy | Comorbidity | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | HIV Protease Inhibitors - therapeutic use | Rhabdomyolysis - prevention & control | Antiretroviral Therapy, Highly Active | Drug Synergism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cost-Benefit Analysis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Dyslipidemias - chemically induced | HIV Infections - complications | Rhabdomyolysis - chemically induced | HIV Infections - drug therapy | Cytochrome P-450 CYP3A Inhibitors - adverse effects
Kidney Tubular Necrosis, Acute - chemically induced | Simvastatin - therapeutic use | Simvastatin - adverse effects | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Humans | Middle Aged | Atorvastatin Calcium - economics | Simvastatin - economics | Simvastatin - pharmacology | Contraindications | HIV Protease Inhibitors - pharmacology | Ritonavir - adverse effects | Ritonavir - therapeutic use | Female | Ritonavir - pharmacology | Drug Substitution - adverse effects | Atorvastatin Calcium - therapeutic use | Chemical and Drug Induced Liver Injury - etiology | HIV Protease Inhibitors - adverse effects | Chemical and Drug Induced Liver Injury - prevention & control | Dyslipidemias - drug therapy | Comorbidity | Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics | HIV Protease Inhibitors - therapeutic use | Rhabdomyolysis - prevention & control | Antiretroviral Therapy, Highly Active | Drug Synergism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cost-Benefit Analysis | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Dyslipidemias - chemically induced | HIV Infections - complications | Rhabdomyolysis - chemically induced | HIV Infections - drug therapy | Cytochrome P-450 CYP3A Inhibitors - adverse effects
Journal Article